Precision Neuroscience Corp
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2026 | $250 M | No. 4 | $250 million to $1 billion | equity, options | SEC | |
| Oct 2024 | $93 M | No. 3 | $50 to $250 million | equity | SEC | |
| Dec 2022 | $41 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2021 | $11 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Precision Neuroscience Corp chose not to state its revenue in its newest notice of a funding round (Sep 2026).
SEC Form D · Sep 2026
The industry group it chose in its notices: Other Health Care.
SEC Form D · Sep 2026
That is all the official record says: Precision Neuroscience Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Precision Neuroscience Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 46 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Benjamin Rapoport | Chief Science Officer | Sep 2026 |
| Craig Mermel | Chief AI and Data Officer | Sep 2026 |
| Konstantinos Alataris | President | Sep 2026 |
| Michael Kaswan | Chief Financial Officer | Sep 2026 |
| Michael Mager | Chief Executive Officer | Sep 2026 |
| MIchael M. Kaswan | Chief Financial Officer | Oct 2024 |
| Benjamin Rapoport | Chief Science Officer | Sep 2026 |
| Craig Mermel | Chief AI and Data Officer | Sep 2026 |
| Howard Morgan | Director | Sep 2026 |
| Konstantinos Alataris | President | Sep 2026 |
| Michael Goller | Director | Sep 2026 |
| Michael Mager | Chief Executive Officer | Sep 2026 |
| Ravi Mehta | Director | Sep 2026 |
| Stephen Biggar | Director | Sep 2026 |
| Eric M. Attias | Director | Oct 2024 |
| Howard M. Morgan | Director | Oct 2024 |
| Jason Chen | Director | Oct 2024 |